11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Gold buy
Period: 31.01.2026 Expectation: 150 pips
Buying gold on dips with $4,500 target
30 December 2025 297
Period: 06.01.2026 Expectation: 2900 pips
Tesla stock selloff on forecasts of declining deliveries and earnings
30 December 2025 137
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Period: 16.01.2026 Expectation: 1000 pips
AUDUSD is consolidating ahead of renewed upside
30 December 2025 127
Period: 06.01.2026 Expectation: 3125 pips
Selling BTCUSD due to lack of momentum after December consolidation
30 December 2025 84
Period: 15.01.2026 Expectation: 100 pips
Investing in SPX from $6,870
30 December 2025 94
Period: 09.01.2026 Expectation: 7500 pips
Silver rally stalls as prices push past $80
29 December 2025 142
Go to forecasts